December 8, 2020
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a
Medical Countermeasure for Smallpox
FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021
TOKYO, Japan, December 8, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio") today announced that Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") announcedon December 7, 2020 (US EST) that the U.S. Food and Drug Administration (FDA) accepted the filingof a New Drug Application (NDA) for antiviral drug brincidofovir (BCV) as a medical countermeasurefor smallpox. The FDA granted Priority Review and set an action date of April 7, 2021 under thePrescription Drug User Fee Act (PDUFA). SymBio, pursuant to a license agreement with Chimerix
entered into on September 30, 2019, obtained the exclusive worldwide rights to develop, manufacture,and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox
infections (which includes smallpox and monkeypox), and SymBio is preparing to initiate a global
study of BCV targeting adenovirus (AdV) infections occurring after hematopoietic stem celltransplantation.
Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoingcollaboration and funding provided by the Biomedical Advanced Research and Development
Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response
within the U.S. Department of Health and Human Services.
For more information, please see Chimerix’s website:
https://ir.chimerix.com/press-releases
Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated: “The completion ofthe NDA filing by Chimerix for BCV to the FDA on a rolling submission basis is a very importantmilestone for us as we continue to develop BCV globally.”1About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating theadvancement of innovative medicines that make a meaningful impact in the lives of patients livingwith cancer and other serious diseases. Its two clinical-stage development programs are dociparstat
sodium (DSTAT) and brincidofovir (BCV).
BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox and iscurrently under review for regulatory approval in the United States. For further information, please
visit the Chimerix website, www.chimerix.com.
About the Global License Agreement for Brincidofovir
SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters:Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of theagreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, andcommercialize BCV in all human indications, excluding the prevention and treatment of orthopox
infections (which includes smallpox and monkeypox). For further information, please see theSymBio’s press release dated October 1, 2019, https://www.symbiopharma.com/news/20191001.pdf
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called
SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

2